



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



PRX-08066

Item No. 31477

CAS Registry No.: 866206-54-4
Formal Name: 5-[[4-[(6-chlorothieno[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl]methyl]-2-fluoro-benzonitrile
MF: C₁₉H₁₇ClFN₅S
FW: 401.9
Purity: ≥95%
UV/Vis.: λ_{max}: 221, 279 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PRX-08066 is supplied as a crystalline solid. A stock solution may be made by dissolving the PRX-08066 in the solvent of choice, which should be purged with an inert gas. PRX-08066 is soluble in ethanol and DMSO. The solubility of PRX-08066 in these solvents is approximately 91 and 96 mg/ml. It is also soluble in water. The solubility of PRX-08066 in water is approximately 95 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

PRX-08066 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT_{2B}.¹ It binds to 5-HT_{2B} receptors (K_i = 3.4 nM) and inhibits 5-HT-induced MAPK activation and thymidine incorporation in CHO cells expressing human 5-HT_{2B} (IC₅₀S = ~12 and ~3 nM, respectively). PRX-08066 (50 and 100 mg/kg) reduces peak pulmonary arterial pressure and right ventricular hypertrophy in a rat model of pulmonary hypertension induced by monocrotaline (MCT; Item No. 16666).

Reference

1. Porvasnik, S.L., Germain, S., Embury, J., *et al.* PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. *J. Pharmacol. Exp. Ther.* **334**(2), 364-372 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/28/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM